Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Identifieur interne : 000178 ( PubMed/Checkpoint ); précédent : 000177; suivant : 000179Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Auteurs : Richard T. Davey [États-Unis] ; Eduardo Fernández-Cruz [Espagne] ; Norman Markowitz [États-Unis] ; Sarah Pett [Royaume-Uni] ; Abdel G. Babiker [Royaume-Uni] ; Deborah Wentworth [États-Unis] ; Surender Khurana [États-Unis] ; Nicole Engen [États-Unis] ; Fred Gordin [États-Unis] ; Mamta K. Jain [États-Unis] ; Virginia Kan [États-Unis] ; Mark N. Polizzotto [Australie] ; Paul Riska [États-Unis] ; Kiat Ruxrungtham [Thaïlande] ; Zelalem Temesgen [États-Unis] ; Jens Lundgren [Danemark] ; John H. Beigel [États-Unis] ; H Clifford Lane [États-Unis] ; James D. Neaton [États-Unis]Source :
- The Lancet. Respiratory medicine [ 2213-2619 ] ; 2019.
Abstract
Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical benefit for patients with influenza infection, but definitive data do not exist. We aimed to evaluate the safety and efficacy of hIVIG in a randomised controlled trial.
DOI: 10.1016/S2213-2600(19)30253-X
PubMed: 31582358
Affiliations:
- Australie, Danemark, Espagne, Royaume-Uni, Thaïlande, États-Unis
- Angleterre, Communauté de Madrid, District de Columbia, Grand Londres, Hovedstaden, Maryland, Michigan, Minnesota, Texas, État de New York
- Copenhague, Londres, Madrid
- University College de Londres
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31582358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.</title><author><name sortKey="Davey, Richard T" sort="Davey, Richard T" uniqKey="Davey R" first="Richard T" last="Davey">Richard T. Davey</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Electronic address: rdavey@niaid.nih.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fernandez Cruz, Eduardo" sort="Fernandez Cruz, Eduardo" uniqKey="Fernandez Cruz E" first="Eduardo" last="Fernández-Cruz">Eduardo Fernández-Cruz</name><affiliation wicri:level="3"><nlm:affiliation>Hospital General Universitario Gregorio Marañón, Servicio de Immunología Clínica, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital General Universitario Gregorio Marañón, Servicio de Immunología Clínica, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Markowitz, Norman" sort="Markowitz, Norman" uniqKey="Markowitz N" first="Norman" last="Markowitz">Norman Markowitz</name><affiliation wicri:level="2"><nlm:affiliation>Henry Ford Hospital, Division of Infectious Diseases, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Henry Ford Hospital, Division of Infectious Diseases, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Pett, Sarah" sort="Pett, Sarah" uniqKey="Pett S" first="Sarah" last="Pett">Sarah Pett</name><affiliation wicri:level="4"><nlm:affiliation>Medical Research Council Clinical Trials Unit, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Clinical Trials Unit, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Babiker, Abdel G" sort="Babiker, Abdel G" uniqKey="Babiker A" first="Abdel G" last="Babiker">Abdel G. Babiker</name><affiliation wicri:level="4"><nlm:affiliation>Medical Research Council Clinical Trials Unit, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Clinical Trials Unit, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Wentworth, Deborah" sort="Wentworth, Deborah" uniqKey="Wentworth D" first="Deborah" last="Wentworth">Deborah Wentworth</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name><affiliation wicri:level="2"><nlm:affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Engen, Nicole" sort="Engen, Nicole" uniqKey="Engen N" first="Nicole" last="Engen">Nicole Engen</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Gordin, Fred" sort="Gordin, Fred" uniqKey="Gordin F" first="Fred" last="Gordin">Fred Gordin</name><affiliation wicri:level="2"><nlm:affiliation>Veteran Affairs Medical Center, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Veteran Affairs Medical Center, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Jain, Mamta K" sort="Jain, Mamta K" uniqKey="Jain M" first="Mamta K" last="Jain">Mamta K. Jain</name><affiliation wicri:level="2"><nlm:affiliation>UT Southwestern Medical Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UT Southwestern Medical Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kan, Virginia" sort="Kan, Virginia" uniqKey="Kan V" first="Virginia" last="Kan">Virginia Kan</name><affiliation wicri:level="2"><nlm:affiliation>Veteran Affairs Medical Center, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Veteran Affairs Medical Center, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Polizzotto, Mark N" sort="Polizzotto, Mark N" uniqKey="Polizzotto M" first="Mark N" last="Polizzotto">Mark N. Polizzotto</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Riska, Paul" sort="Riska, Paul" uniqKey="Riska P" first="Paul" last="Riska">Paul Riska</name><affiliation wicri:level="2"><nlm:affiliation>Montefiore Medical Center, Bronx, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Montefiore Medical Center, Bronx, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Temesgen, Zelalem" sort="Temesgen, Zelalem" uniqKey="Temesgen Z" first="Zelalem" last="Temesgen">Zelalem Temesgen</name><affiliation wicri:level="2"><nlm:affiliation>Mayo Clinic Hospital, Saint Marys Campus, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic Hospital, Saint Marys Campus, Rochester, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Lundgren, Jens" sort="Lundgren, Jens" uniqKey="Lundgren J" first="Jens" last="Lundgren">Jens Lundgren</name><affiliation wicri:level="3"><nlm:affiliation>CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Beigel, John H" sort="Beigel, John H" uniqKey="Beigel J" first="John H" last="Beigel">John H. Beigel</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Lane, H Clifford" sort="Lane, H Clifford" uniqKey="Lane H" first="H Clifford" last="Lane">H Clifford Lane</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Neaton, James D" sort="Neaton, James D" uniqKey="Neaton J" first="James D" last="Neaton">James D. Neaton</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31582358</idno><idno type="pmid">31582358</idno><idno type="doi">10.1016/S2213-2600(19)30253-X</idno><idno type="wicri:Area/PubMed/Corpus">000089</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000089</idno><idno type="wicri:Area/PubMed/Curation">000089</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000089</idno><idno type="wicri:Area/PubMed/Checkpoint">000178</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000178</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.</title><author><name sortKey="Davey, Richard T" sort="Davey, Richard T" uniqKey="Davey R" first="Richard T" last="Davey">Richard T. Davey</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Electronic address: rdavey@niaid.nih.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fernandez Cruz, Eduardo" sort="Fernandez Cruz, Eduardo" uniqKey="Fernandez Cruz E" first="Eduardo" last="Fernández-Cruz">Eduardo Fernández-Cruz</name><affiliation wicri:level="3"><nlm:affiliation>Hospital General Universitario Gregorio Marañón, Servicio de Immunología Clínica, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital General Universitario Gregorio Marañón, Servicio de Immunología Clínica, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Markowitz, Norman" sort="Markowitz, Norman" uniqKey="Markowitz N" first="Norman" last="Markowitz">Norman Markowitz</name><affiliation wicri:level="2"><nlm:affiliation>Henry Ford Hospital, Division of Infectious Diseases, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Henry Ford Hospital, Division of Infectious Diseases, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Pett, Sarah" sort="Pett, Sarah" uniqKey="Pett S" first="Sarah" last="Pett">Sarah Pett</name><affiliation wicri:level="4"><nlm:affiliation>Medical Research Council Clinical Trials Unit, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Clinical Trials Unit, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Babiker, Abdel G" sort="Babiker, Abdel G" uniqKey="Babiker A" first="Abdel G" last="Babiker">Abdel G. Babiker</name><affiliation wicri:level="4"><nlm:affiliation>Medical Research Council Clinical Trials Unit, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Clinical Trials Unit, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Wentworth, Deborah" sort="Wentworth, Deborah" uniqKey="Wentworth D" first="Deborah" last="Wentworth">Deborah Wentworth</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name><affiliation wicri:level="2"><nlm:affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Engen, Nicole" sort="Engen, Nicole" uniqKey="Engen N" first="Nicole" last="Engen">Nicole Engen</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Gordin, Fred" sort="Gordin, Fred" uniqKey="Gordin F" first="Fred" last="Gordin">Fred Gordin</name><affiliation wicri:level="2"><nlm:affiliation>Veteran Affairs Medical Center, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Veteran Affairs Medical Center, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Jain, Mamta K" sort="Jain, Mamta K" uniqKey="Jain M" first="Mamta K" last="Jain">Mamta K. Jain</name><affiliation wicri:level="2"><nlm:affiliation>UT Southwestern Medical Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UT Southwestern Medical Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kan, Virginia" sort="Kan, Virginia" uniqKey="Kan V" first="Virginia" last="Kan">Virginia Kan</name><affiliation wicri:level="2"><nlm:affiliation>Veteran Affairs Medical Center, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Veteran Affairs Medical Center, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Polizzotto, Mark N" sort="Polizzotto, Mark N" uniqKey="Polizzotto M" first="Mark N" last="Polizzotto">Mark N. Polizzotto</name><affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales Australia, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute, University of New South Wales Australia, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Riska, Paul" sort="Riska, Paul" uniqKey="Riska P" first="Paul" last="Riska">Paul Riska</name><affiliation wicri:level="2"><nlm:affiliation>Montefiore Medical Center, Bronx, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Montefiore Medical Center, Bronx, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Temesgen, Zelalem" sort="Temesgen, Zelalem" uniqKey="Temesgen Z" first="Zelalem" last="Temesgen">Zelalem Temesgen</name><affiliation wicri:level="2"><nlm:affiliation>Mayo Clinic Hospital, Saint Marys Campus, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic Hospital, Saint Marys Campus, Rochester, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Lundgren, Jens" sort="Lundgren, Jens" uniqKey="Lundgren J" first="Jens" last="Lundgren">Jens Lundgren</name><affiliation wicri:level="3"><nlm:affiliation>CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Beigel, John H" sort="Beigel, John H" uniqKey="Beigel J" first="John H" last="Beigel">John H. Beigel</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Lane, H Clifford" sort="Lane, H Clifford" uniqKey="Lane H" first="H Clifford" last="Lane">H Clifford Lane</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Neaton, James D" sort="Neaton, James D" uniqKey="Neaton J" first="James D" last="Neaton">James D. Neaton</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Respiratory medicine</title><idno type="eISSN">2213-2619</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical benefit for patients with influenza infection, but definitive data do not exist. We aimed to evaluate the safety and efficacy of hIVIG in a randomised controlled trial.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">31582358</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2619</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Respiratory medicine</Title><ISOAbbreviation>Lancet Respir Med</ISOAbbreviation></Journal><ArticleTitle>Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>951-963</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2213-2600(19)30253-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-2600(19)30253-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical benefit for patients with influenza infection, but definitive data do not exist. We aimed to evaluate the safety and efficacy of hIVIG in a randomised controlled trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomised, double-blind, placebo-controlled trial was planned for 45 hospitals in Argentina, Australia, Denmark, Greece, Mexico, Spain, Thailand, UK, and the USA over five influenza seasons from 2013-14 to 2017-18. Adults (≥18 years of age) were admitted for hospital treatment with laboratory-confirmed influenza A or B infection and were randomly assigned (1:1) to receive standard care plus either a single 500-mL infusion of high-titre hIVIG (0·25 g/kg bodyweight, 24·75 g maximum; hIVIG group) or saline placebo (placebo group). Eligible patients had a National Early Warning score of 2 points or greater at the time of screening and their symptoms began no more than 7 days before randomisation. Pregnant and breastfeeding women were excluded, as well as any patients for whom the treatment would present a health risk. Separate randomisation schedules were generated for each participating clinical site using permuted block randomisation. Treatment assignments were obtained using a web-based application by the site pharmacist who then masked the solution for infusion. Patients and investigators were masked to study treatment. The primary endpoint was a six-category ordinal outcome of clinical status at day 7, ranging in severity from death to resumption of normal activities after discharge. The choice of day 7 was based on haemagglutination inhibition titres from a pilot study. It was analysed with a proportional odds model, using all six categories to estimate a common odds ratio (OR). An OR greater than 1 indicated that, for a given category, patients in the hIVIG group were more likely to be in a better category than those in the placebo group. Prespecified primary analyses for safety and efficacy were based on patients who received an infusion and for whom eligibility could be confirmed. This trial is registered with ClinicalTrials.gov, NCT02287467.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">313 patients were enrolled in 34 sites between Dec 11, 2014, and May 28, 2018. We also used data from 16 patients enrolled at seven of the 34 sites during the pilot study between Jan 15, 2014, and April 10, 2014. 168 patients were randomly assigned to the hIVIG group and 161 to the placebo group. 21 patients were excluded (12 from the hIVIG group and 9 from the placebo group) because they did not receive an infusion or their eligibility could not be confirmed. Thus, 308 were included in the primary analysis. hIVIG treatment produced a robust rise in haemagglutination inhibition titres against influenza A and smaller rises in influenza B titres. Based on the proportional odds model, the OR on day 7 was 1·25 (95% CI 0·79-1·97; p=0·33). In subgroup analyses for the primary outcome, the OR in patients with influenza A was 0·94 (0·55-1·59) and was 3·19 (1·21-8·42) for those with influenza B (interaction p=0·023). Through 28 days of follow-up, 47 (30%) of 156 patients in the hIVIG group and in 45 (30%) of 152 patients in the placebo group had the composite safety outcome of death, a serious adverse event, or a grade 3 or 4 adverse event (hazard ratio [HR] 1·06, 95% CI 0·70-1·60; p=0·79). Six (4%) patients in the hIVIG group and five (3%) in the placebo group died, but these deaths were not necessarily related to treatment.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">When administered alongside standard care (most commonly oseltamivir), hIVIG was not superior to placebo for adults hospitalised with influenza infection. By contrast with our prespecified subgroup hypothesis that hIVIG would result in more favourable responses in patients with influenza A than B, we found the opposite effect. The clinical benefit of hIVIG for patients with influenza B is supported by antibody affinity analyses, but confirmation is warranted.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">NIAID and NIH. Partial support was provided by the Medical Research Council (MRC_UU_12023/23) and the Danish National Research Foundation.</AbstractText><CopyrightInformation>Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davey</LastName><ForeName>Richard T</ForeName><Initials>RT</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Electronic address: rdavey@niaid.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Cruz</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital General Universitario Gregorio Marañón, Servicio de Immunología Clínica, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markowitz</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Henry Ford Hospital, Division of Infectious Diseases, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pett</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Council Clinical Trials Unit, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babiker</LastName><ForeName>Abdel G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Medical Research Council Clinical Trials Unit, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wentworth</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Surender</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engen</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordin</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Veteran Affairs Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Mamta K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>UT Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kan</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Veteran Affairs Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polizzotto</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales Australia, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riska</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruxrungtham</LastName><ForeName>Kiat</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temesgen</LastName><ForeName>Zelalem</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Mayo Clinic Hospital, Saint Marys Campus, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beigel</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>H Clifford</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neaton</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>INSIGHT FLU-IVIG Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02287467</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>HHSN261201500003C</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261201000031C</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261201500001C</GrantID><Acronym>RC</Acronym><Agency>CCR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261201500001G</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001C</GrantID><Acronym>RC</Acronym><Agency>CCR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261201500001W</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001E</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Respir Med</MedlineTA><NlmUniqueID>101605555</NlmUniqueID><ISSNLinking>2213-2600</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><InvestigatorList><Investigator ValidYN="Y"><LastName>Davey</LastName><ForeName>Richard T</ForeName><Initials>RT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernández-Cruz</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markowitz</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pett</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babiker</LastName><ForeName>Abdel G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wentworth</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khurana</LastName><ForeName>Surender</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engen</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordin</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>Mamta K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kan</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polizzotto</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riska</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruxrungtham</LastName><ForeName>Kiat</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Temesgen</LastName><ForeName>Zelalem</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beigel</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>H Clifford</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neaton</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butts</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denning</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>DuChene</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krum</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrison</LastName><ForeName>Merrie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meger</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Ross</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quan</LastName><ForeName>Kien</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaughnessy</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vock</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metcalf</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewar</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rehman</LastName><ForeName>Tauseef</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Ven</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>McConnell</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flowers</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Kenny</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoover</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coyle</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munroe</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aagaard</LastName><ForeName>Bitten</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cursley</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Webb</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Fleur</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sy</LastName><ForeName>Aminata</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Purvis</LastName><ForeName>Cara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Brooke</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collaco-Moraes</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carey</LastName><ForeName>Dianne</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robson</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sánchez</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finley</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conwell</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Losso</LastName><ForeName>Marcelo H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gambardella</LastName><ForeName>Luciana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abela</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Paco</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alonso</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touloumi</LastName><ForeName>Giota</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gioukari</LastName><ForeName>Vicky</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anagnostou</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avihingsanon</LastName><ForeName>Anchalee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pussadee</LastName><ForeName>Kanitta</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ubolyam</LastName><ForeName>Sasiwimol</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Omotosho</LastName><ForeName>Bola</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solórzano</LastName><ForeName>Clemencia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Tianna</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vysyaraju</LastName><ForeName>Kranthi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizza</LastName><ForeName>Stacey A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitaker</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nahra</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baxter</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coburn</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardner</LastName><ForeName>Edward M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pastor</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makohon</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Rodger A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hillman</LastName><ForeName>L Monique</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrough</LastName><ForeName>Marti J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polenakovik</LastName><ForeName>Hari M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Linda A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colon</LastName><ForeName>Roberto J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunisaki</LastName><ForeName>Ken M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeConcini</LastName><ForeName>Miranda</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Susan A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Cameron R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mkumba</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carbonneau</LastName><ForeName>June Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kessinger</LastName><ForeName>Cathy J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salata</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arters</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tasi</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panos</LastName><ForeName>Ralph J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lach</LastName><ForeName>Laura A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glesby</LastName><ForeName>Marshall J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ham</LastName><ForeName>Kirsis A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hughes</LastName><ForeName>Valery G</ForeName><Initials>VG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schooley</LastName><ForeName>Robert T</ForeName><Initials>RT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crouch</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muttera</LastName><ForeName>Leticia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novak</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bleasdale</LastName><ForeName>Susan C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zuckerman</LastName><ForeName>Ariel E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manosuthi</LastName><ForeName>Weerawat</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thaonyen</LastName><ForeName>Supeda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiewcharn</LastName><ForeName>Thaniya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suwanpimolkul</LastName><ForeName>Gompol</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatechumpol</LastName><ForeName>Sivaporn</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bunpasang</LastName><ForeName>Sirikunya</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Angus</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minton</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gkamaletsou</LastName><ForeName>Maria N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hambleton</LastName><ForeName>Joe</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llewelyn</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweetman</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carbone</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arribas</LastName><ForeName>Jose R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montejano</LastName><ForeName>Rocio</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobo Beristain</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Iñaki Z</ForeName><Initials>IZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barberan</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dwyer</LastName><ForeName>Dominic E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kok</LastName><ForeName>Jen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borges</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandt</LastName><ForeName>Christian T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Lene S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sypsas</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Constantinou</LastName><ForeName>Costas</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markogiannakis</LastName><ForeName>Antonios</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zakynthinos</LastName><ForeName>Spyros</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katsaounou</LastName><ForeName>Paraskevi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalomenidis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mykietiuk</LastName><ForeName>Analia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alzogaray</LastName><ForeName>Maria F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obed</LastName><ForeName>Mora</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macias</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ebensrtejin</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgoa</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nannini</LastName><ForeName>Esteban</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lahitte</LastName><ForeName>Matias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez-Patrigeon</LastName><ForeName>Santiago</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martínez-Orozco</LastName><ForeName>José Arturo</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramírez-Hinojosa</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>06</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31582358</ArticleId><ArticleId IdType="pii">S2213-2600(19)30253-X</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(19)30253-X</ArticleId><ArticleId IdType="pmc">PMC6868512</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2014 Nov 12;32(48):6421-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25284811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Dec 15;204(12):1879-85</Citation><ArticleIdList><ArticleId IdType="pubmed">21998477</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2018 Sep;17(9):785-795</Citation><ArticleIdList><ArticleId IdType="pubmed">30145912</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2018 Mar 31;391(10127):1285-1300</Citation><ArticleIdList><ArticleId IdType="pubmed">29248255</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2018 Aug 16;67(5):736-742</Citation><ArticleIdList><ArticleId IdType="pubmed">29659754</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Trials. 2017 Jun;14(3):264-276</Citation><ArticleIdList><ArticleId IdType="pubmed">28397569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2006 Oct 17;145(8):599-609</Citation><ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2013 Aug;144(2):464-473</Citation><ArticleIdList><ArticleId IdType="pubmed">23450336</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2018 Dec 1;187(12):2511-2523</Citation><ArticleIdList><ArticleId IdType="pubmed">30124746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2016 Feb 15;213(4):574-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26374911</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2013 Oct;183(4):1258-1268</Citation><ArticleIdList><ArticleId IdType="pubmed">23938324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation><ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2017 Aug 12;390(10095):697-708</Citation><ArticleIdList><ArticleId IdType="pubmed">28302313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 May 2;385(9979):1729-1737</Citation><ArticleIdList><ArticleId IdType="pubmed">25640810</ArticleId></ArticleIdList></Reference><Reference><Citation>EBioMedicine. 2017 May;19:119-127</Citation><ArticleIdList><ArticleId IdType="pubmed">28408242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jan 15;33(4):500-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25498210</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 1993 Dec 30;12(24):2257-71</Citation><ArticleIdList><ArticleId IdType="pubmed">8134732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2011 Jun 1;3(85):85ra48</Citation><ArticleIdList><ArticleId IdType="pubmed">21632986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 2005 May;22(5):511-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15892597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2017 Jun;5(6):500-511</Citation><ArticleIdList><ArticleId IdType="pubmed">28522352</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1979 Sep;35(3):549-56</Citation><ArticleIdList><ArticleId IdType="pubmed">497341</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2019 May 2;68(10):1713-1717</Citation><ArticleIdList><ArticleId IdType="pubmed">30202873</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2019 Nov;7(11):941-950</Citation><ArticleIdList><ArticleId IdType="pubmed">31582360</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull Hist Med. 2002 Spring;76(1):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11875246</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Danemark</li><li>Espagne</li><li>Royaume-Uni</li><li>Thaïlande</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Communauté de Madrid</li><li>District de Columbia</li><li>Grand Londres</li><li>Hovedstaden</li><li>Maryland</li><li>Michigan</li><li>Minnesota</li><li>Texas</li><li>État de New York</li></region><settlement><li>Copenhague</li><li>Londres</li><li>Madrid</li></settlement><orgName><li>University College de Londres</li></orgName></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Davey, Richard T" sort="Davey, Richard T" uniqKey="Davey R" first="Richard T" last="Davey">Richard T. Davey</name></region><name sortKey="Beigel, John H" sort="Beigel, John H" uniqKey="Beigel J" first="John H" last="Beigel">John H. Beigel</name><name sortKey="Engen, Nicole" sort="Engen, Nicole" uniqKey="Engen N" first="Nicole" last="Engen">Nicole Engen</name><name sortKey="Gordin, Fred" sort="Gordin, Fred" uniqKey="Gordin F" first="Fred" last="Gordin">Fred Gordin</name><name sortKey="Jain, Mamta K" sort="Jain, Mamta K" uniqKey="Jain M" first="Mamta K" last="Jain">Mamta K. Jain</name><name sortKey="Kan, Virginia" sort="Kan, Virginia" uniqKey="Kan V" first="Virginia" last="Kan">Virginia Kan</name><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name><name sortKey="Lane, H Clifford" sort="Lane, H Clifford" uniqKey="Lane H" first="H Clifford" last="Lane">H Clifford Lane</name><name sortKey="Markowitz, Norman" sort="Markowitz, Norman" uniqKey="Markowitz N" first="Norman" last="Markowitz">Norman Markowitz</name><name sortKey="Neaton, James D" sort="Neaton, James D" uniqKey="Neaton J" first="James D" last="Neaton">James D. Neaton</name><name sortKey="Riska, Paul" sort="Riska, Paul" uniqKey="Riska P" first="Paul" last="Riska">Paul Riska</name><name sortKey="Temesgen, Zelalem" sort="Temesgen, Zelalem" uniqKey="Temesgen Z" first="Zelalem" last="Temesgen">Zelalem Temesgen</name><name sortKey="Wentworth, Deborah" sort="Wentworth, Deborah" uniqKey="Wentworth D" first="Deborah" last="Wentworth">Deborah Wentworth</name></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Fernandez Cruz, Eduardo" sort="Fernandez Cruz, Eduardo" uniqKey="Fernandez Cruz E" first="Eduardo" last="Fernández-Cruz">Eduardo Fernández-Cruz</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Pett, Sarah" sort="Pett, Sarah" uniqKey="Pett S" first="Sarah" last="Pett">Sarah Pett</name></region><name sortKey="Babiker, Abdel G" sort="Babiker, Abdel G" uniqKey="Babiker A" first="Abdel G" last="Babiker">Abdel G. Babiker</name></country><country name="Australie"><noRegion><name sortKey="Polizzotto, Mark N" sort="Polizzotto, Mark N" uniqKey="Polizzotto M" first="Mark N" last="Polizzotto">Mark N. Polizzotto</name></noRegion></country><country name="Thaïlande"><noRegion><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name></noRegion></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Lundgren, Jens" sort="Lundgren, Jens" uniqKey="Lundgren J" first="Jens" last="Lundgren">Jens Lundgren</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000178 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000178 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31582358
|texte= Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31582358" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |